$13.2 M

BSTG Mkt cap, 22-Sept-2020
Biostage Net income (Q2, 2020)-1.2 M
Biostage EBIT (Q2, 2020)-1.3 M
Biostage Cash, 30-Jun-2020618 K
Biostage EV13.3 M

Biostage Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

22.0k93.0k118.0k82.0k

Revenue growth, %

323%27%(31%)

Cost of goods sold

11.0k48.0k139.0k116.0k

Gross profit

11.0k45.0k(21.0k)(34.0k)

Gross profit Margin, %

50%48%(18%)(41%)

Sales and marketing expense

259.0k329.0k289.0k

R&D expense

4.6m5.1m4.8m7.6m7.6m3.9m4.9m

General and administrative expense

4.0m5.7m6.6m4.5m3.9m3.9m4.0m

Operating expense total

8.8m11.1m11.7m12.1m11.5m7.8m8.9m

EBIT

(8.8m)(11.1m)(11.7m)(12.1m)(11.5m)(7.8m)(8.9m)

EBIT margin, %

(40077%)(11889%)(9916%)(14788%)

Interest expense

4.0k3.0k448.0k312.0k

Pre tax profit

(8.8m)(11.1m)(11.7m)(11.6m)(11.9m)

Net Income

(8.8m)(11.1m)(11.7m)(11.6m)(11.9m)(7.5m)(8.3m)

Biostage Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

14.0m5.3m7.5m2.9m4.0m1.3m913.0k

Accounts Receivable

5.0k21.0k42.0k

Prepaid Expenses

421.0k317.0k330.0k289.0k623.0k444.0k

Inventories

38.0k207.0k75.0k

Current Assets

14.5m5.8m7.9m3.5m4.4m2.2m1.4m

PP&E

575.0k1.4m1.1m1.1m632.0k479.0k394.0k

Total Assets

15.1m7.2m9.0m4.6m5.0m2.6m2.0m

Accounts Payable

244.0k370.0k357.0k962.0k923.0k160.0k241.0k

Short-term debt

102.0k

Current Liabilities

495.0k710.0k654.0k2.8m1.6m662.0k814.0k

Long-term debt

280.0k

Non-Current Liabilities

Total Debt

382.0k

Total Liabilities

495.0k710.0k654.0k2.8m1.6m662.0k903.0k

Common Stock

77.0k79.0k141.0k25.0k57.0k82.0k

Additional Paid-in Capital

16.5m19.4m32.9m37.9m50.2m57.7m65.1m

Retained Earnings

(2.0m)(13.0m)(24.7m)(36.3m)(48.2m)(55.8m)(64.1m)

Total Equity

14.6m6.5m8.3m1.8m3.4m2.0m1.1m

Financial Leverage

1 x1.1 x1.1 x2.6 x1.5 x1.3 x1.8 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

12.6m10.1m7.7m12.2m10.1m8.2m4.8m8.1m6.0m6.6m3.4m1.3m2.8m5.8m3.5m1.1m1.3m1.1m806.0k618.0k

Accounts Receivable

29.0k81.0k59.0k18.0k40.0k66.0k37.0k

Prepaid Expenses

33.0k349.0k356.0k117.0k269.0k173.0k82.0k485.0k156.0k96.0k249.0k178.0k94.0k357.0k228.0k229.0k499.0k516.0k248.0k346.0k273.0k

Inventories

129.0k146.0k157.0k212.0k201.0k144.0k79.0k47.0k41.0k

Current Assets

33.0k13.1m10.6m8.1m12.6m10.6m8.5m5.4m8.3m6.2m6.9m3.7m1.7m3.3m6.2m3.9m1.7m2.0m1.5m1.2m941.0k

PP&E

460.0k760.0k1.0m1.4m1.3m1.2m1.2m1.1m1.1m988.0k1.0m957.0k875.0k586.0k573.0k544.0k466.0k477.0k432.0k346.0k300.0k

Total Assets

493.0k13.9m11.7m9.4m13.9m11.8m9.7m6.6m9.4m7.2m8.0m4.7m2.6m3.9m6.8m4.5m2.3m2.6m2.1m1.7m1.4m

Accounts Payable

126.0k406.0k434.0k254.0k261.0k317.0k220.0k264.0k596.0k803.0k713.0k687.0k1.2m239.0k167.0k204.0k311.0k251.0k270.0k227.0k141.0k

Short-term debt

105.0k257.0k

Current Liabilities

379.0k872.0k825.0k716.0k674.0k590.0k331.0k388.0k1.9m2.4m6.4m3.4m2.1m809.0k1.4m938.0k956.0k895.0k918.0k1.0m864.0k

Long-term debt

44.0k25.0k23.0k227.0k429.0k

Non-Current Liabilities

Total Debt

44.0k25.0k23.0k332.0k686.0k

Total Liabilities

379.0k872.0k825.0k716.0k674.0k590.0k331.0k388.0k1.9m2.4m6.4m3.4m2.1m809.0k1.4m938.0k1.0m920.0k941.0k1.1m1.2m

Common Stock

78.0k78.0k79.0k101.0k110.0k127.0k141.0k171.0k171.0k371.0k371.0k398.0k29.0k57.0k57.0k62.0k70.0k76.0k85.0k87.0k

Preferred Stock

5.2m3.8m1.2m

Additional Paid-in Capital

17.9m18.3m18.8m23.6m27.5m30.5m33.3m37.2m37.6m41.3m44.7m47.1m51.3m57.2m57.4m59.0m61.8m63.5m66.7m67.4m

Retained Earnings

(18.6m)(5.0m)(7.5m)(10.2m)(15.7m)(20.2m)(22.4m)(27.2m)(29.9m)(33.0m)(40.2m)(43.8m)(47.0m)(49.8m)(51.8m)(53.9m)(57.7m)(60.1m)(62.5m)(66.1m)(67.3m)

Total Equity

13.0m10.9m8.7m13.2m11.2m9.4m6.2m7.5m4.8m1.5m1.3m477.0k3.0m5.4m3.5m1.3m1.7m1.1m644.0k230.0k

Financial Leverage

1.1 x1.1 x1.1 x1.1 x1.1 x1 x1.1 x1.3 x1.5 x5.2 x3.6 x5.4 x1.3 x1.3 x1.3 x1.7 x1.5 x1.8 x2.7 x6 x

Biostage Cash Flow

Annual

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(6.2m)(3.0m)(5.5m)(8.2m)(2.6m)(7.1m)(9.4m)(2.5m)(5.2m)(8.2m)(3.8m)(7.4m)(10.7m)(1.5m)(3.6m)(5.7m)(1.9m)(4.4m)(6.7m)(2.0m)(3.2m)

Depreciation and Amortization

123.0k56.0k151.0k256.0k112.0k226.0k347.0k111.0k224.0k340.0k121.0k236.0k334.0k63.0k128.0k194.0k61.0k115.0k165.0k48.0k94.0k

Accounts Receivable

(29.0k)5.0k(76.0k)(54.0k)3.0k(19.0k)(45.0k)5.0k42.0k42.0k

Inventories

(91.0k)(108.0k)(119.0k)(5.0k)6.0k63.0k(4.0k)28.0k34.0k

Accounts Payable

(53.0k)162.0k71.0k10.0k(109.0k)(83.0k)(150.0k)(137.0k)230.0k418.0k(249.0k)(275.0k)246.0k(698.0k)(759.0k)(721.0k)127.0k56.0k110.0k(14.0k)(100.0k)

Cash From Operating Activities

(5.6m)(1.4m)(3.8m)(5.7m)(1.7m)(3.7m)(5.6m)(2.5m)(4.0m)(6.1m)(3.1m)(6.2m)(9.4m)(2.1m)(3.2m)(5.5m)(1.2m)(3.3m)(4.6m)(1.1m)(2.2m)

Purchases of PP&E

(145.0k)(242.0k)(495.0k)(1.0m)(6.0k)(21.0k)(175.0k)(128.0k)(217.0k)(225.0k)(105.0k)(125.0k)(140.0k)(3.0k)(89.0k)(127.0k)(24.0k)(78.0k)(118.0k)

Cash From Investing Activities

(145.0k)(242.0k)(495.0k)(1.0m)(6.0k)(21.0k)(175.0k)(128.0k)(217.0k)(225.0k)(105.0k)(125.0k)(140.0k)46.0k(25.0k)(63.0k)(24.0k)(78.0k)(118.0k)

Cash From Financing Activities

5.7m247.0k358.0k418.0k8.6m8.6m8.7m4.8m4.8m6.8m6.8m7.9m795.0k5.0m5.0m1.0m3.3m4.5m987.0k1.9m

Net Change in Cash

(1.4m)(3.9m)(6.3m)6.9m4.9m2.9m(2.6m)644.0k(1.4m)3.6m483.0k(1.6m)(1.2m)1.8m(495.0k)(240.0k)(54.0k)(207.0k)(107.0k)(295.0k)

Biostage Ratios

USDQ3, 2013